Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score

Clinical and Translational Allergy

Volumn 5, Issue 1, 2015, Pages

  Didier, Alain ^a   Malling, Hans Jørgen ^b   Worm, Margitta ^c   Horak, Friedrich ^d   Sussman, Gordon L ^e  

^a SERVICE DE PNEUMOLOGIE   (France)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Vienna Challenge Chamber   (Austria)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

5 grass pollen tablet; Allergen specific immunotherapy; Allergic rhinitis; Allergic rhinoconjunctivitis; Long term efficacy Sublingual immunotherapy

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; PLACEBO; POLLEN EXTRACT;

ADULT; ALLERGIC DISEASE; ALLERGIC RHINITIS; ALLERGY; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL PROTOCOL; CONTROLLED STUDY; DAILY COMBINED SCORE; DAILY RESCUE MEDICATION SCORE; DAILY RHINOCONJUNCTIVITIS TOTAL SYMPTOM SCORE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRASS POLLEN; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; SCORING SYSTEM; TABLET FORMULATION; TREATMENT RESPONSE;

EID: 85006136242     PISSN: None     EISSN: 20457022     Source Type: Journal    
DOI: 10.1186/s13601-015-0057-8     Document Type: Article

References (23)

1. Ozdoganoglu T, Songu M. The burden of allergic rhinitis and asthma. Ther Adv Respir Dis. 2012;6:11-23.
2. World Allergy Organization. WAO White Book on Allergy Update 2013. Milwaukee, WI: World Allergy Organization; 2014.
3. Cox LS, Casale TB, Nayak AS, Bernstein DI, Creticos PS, Ambroisine L, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol. 2012;130:1327-34. e1321.
4. Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;120:1338-45.
5. Wahn U, Tabar A, Kuna P, Halken S, Montagut A, de Beaumont O, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009;123:160-6. e163.
6. Horak F, Zieglmayer P, Zieglmayer R, Lemell P, Devillier P, Montagut A, et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol. 2009;124:471-7. 477 e471.
7. Malling HJ, Montagut A, Melac M, Patriarca G, Panzner P, Seberova E, et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin Exp Allergy. 2009;39:387-93.
8. Clark J, Schall R. Assessment of combined symptom and medication scores for rhinoconjunctivitis immunotherapy clinical trials. Allergy. 2007;62:1023-8.
9. Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy. 2007;62:317-24.
10. Pfaar O, Demoly P, Gerth van Wijk R, Bonini S, Bousquet J, Canonica GW, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014;69:854-67.
11. Committee for Medicinal Products for Human Use (CHMP), Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases (CHMP/EWP/18504/2006). [ http://www.ema.europa.eu/ema/pages/includes/document/open-document.jsp?webContentId=WC500003605 ]
12. Didier A, Worm M, Horak F, Sussman G, de Beaumont O, Le Gall M, et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol. 2011;128:559-66.
13. Didier A, Malling HJ, Worm M, Horak F, Sussman G, Melac M, et al. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Clin Exp Allergy. 2013;43:568-77.
14. Grouin JM, Vicaut E, Jean-Alphonse S, Demoly P, Wahn U, Didier A, et al. The average Adjusted Symptom Score, a new primary efficacy end-point for specific allergen immunotherapy trials. Clin Exp Allergy. 2011;41:1282-8.
15. Calderon MA, Bernstein DI, Blaiss M, Andersen JS, Nolte H. A comparative analysis of symptom and medication scoring methods used in clinical trials of sublingual immunotherapy for seasonal allergic rhinitis. Clin Exp Allergy. 2014;44:1228-39.
16. Global Initiative for Asthma. GINA Report, Global Strategy for Asthma Management and Prevention. [ http://www.ginasthma.org/local/uploads/files/GINA-Report-2014-Aug12.pdf ]
17. Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129:717-25. e715.
18. MK-7743 timothy Grass Pollen Extract Tablets Advisory Committee Meeting Briefing Document. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/AllergenicProductsAdvisoryCommittee/UCM378093.pdf. 11-12 December 2013
19. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63 Suppl 86:8-160.
20. Casale TB, Canonica GW, Bousquet J, Cox L, Lockey R, Nelson HS, et al. Recommendations for appropriate sublingual immunotherapy clinical trials. J Allergy Clin Immunol. 2009;124:665-70.
21. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127:S1-55.
22. Moingeon P, Peltre G, Bergmann KC. Rationale for a five-grass pollen vaccine. Clin Exp Allerg Rev. 2008;8:12-4.
23. Didier A, Wahn U, Horak F, Cox LS. Five-grass pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience. Expert Rev Clin Immunol. 2014;10:1309-24.